New drug ESG406 enters human testing for Hard-to-Treat cancers
NCT ID NCT06979674
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called ESG406 in 556 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first find a safe dose, then expand to see if the drug can shrink tumors. The main focus is on safety and tolerability, with tumor response as a secondary goal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ESG406 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects are unknown. Results may not apply to all tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
Contact
-
The First Affiliated Hospital of Xi 'An Jiaotong University
RECRUITINGXi’an, Shanxi, 710061, China
Contact
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact